Veracyte, Inc. (12V.F)
Chart Events
Performance Outlook
| Previous Close | 23.80 |
| Open | 23.20 |
| Bid | 0.00 x 36100 |
| Ask | 0.00 x 34700 |
| Day's Range | 23.20 - 23.20 |
| 52 Week Range | 18.50 - 27.72 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 1.734B |
| Beta (5Y Monthly) | 1.70 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.64 |
| Earnings Date | Feb 20, 2024 - Feb 26, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 63.17 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for 12V.F
Related Research
Business WireReal-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
SOUTH SAN FRANCISCO, Calif., December 01, 2023--Veracyte, Inc. (Nasdaq: VCYT) announced that new data presented today at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023) highlight clinical observations and translational research conducted by users of the company’s Decipher Prostate Genomic Classifier. These independent, real-world studies provide further evidence supporting the clinical utility of the test in the treatment and management of prostate cancer, particularly for
Business WireClinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
SOUTH SAN FRANCISCO, Calif., November 29, 2023--Clinical Validation Data for Veracyte's Percepta Nasal Swab Test Published in CHEST
Business WireVeracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023
SOUTH SAN FRANCISCO, Calif., November 22, 2023--Veracyte, Inc. (Nasdaq: VCYT) today announced that seven posters will be presented at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023), where they will demonstrate the clinical performance of Veracyte’s Decipher Prostate Genomic Classifier in identifying patients whose prostate cancer is likely to progress and require treatment. Collectively, the posters will report data from more than 60,000 patients. The meeting will take pl
